

**In The Claims**

1. (currently amended) A bispecific immunoglobulin molecule that comprises a first binding domain comprising ~~a first immunoglobulin variable region comprising~~ V<sub>L</sub> and V<sub>H</sub> domains of monoclonal antibody cmHsp70.1 as produced by hybridoma cmHsp70.1, deposited with the DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1 b, D-38124 Braunschweig, Germany on November 14, 2003, and assigned Accession Number DSM ACC2629 or ~~from V<sub>L</sub> and V<sub>H</sub> domains of monoclonal antibody~~ cmHsp70.2 as produced by the hybridoma cmHsp70.2, deposited with the DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH on November 14, 2003, and assigned Accession Number DSM ACC2630 which binds cell surface membrane-bound heat shock protein 70 (Hsp) (Hsp70) and a second binding domain comprising ~~a second immunoglobulin variable region comprising~~ V<sub>L</sub> and V<sub>H</sub> domains which binds a member of the anti-apoptotic Bcl-2-associated athanogene (Bag) family, wherein the bispecific molecule is capable of specifically binding its target antigen on viable tumor cells.
2. (canceled)
3. (currently amended) The bispecific molecule of claim 1, wherein said member of the Bag family is Bag-4.
4. (currently amended) The bispecific molecule of claim 1, wherein said first binding domain binds to the C-terminal domain of the Hsp Hsp70 and said second binding domain binds to the C-terminal domain of Bag protein.
5. (cancelled).
6. (previously presented) The bispecific molecule of claim 1, which is a dimeric molecule.

7. (previously presented) The bispecific molecule of claim 1, which has at least one further functional domain.

8. – 14. (cancelled)

15. (previously presented) The bispecific molecule of claim 7, wherein said further functional domain is a cytotoxic agent or a label.

16. – 21. (cancelled)

22. – 55. (cancelled)

56. (previously presented) The bispecific molecule of claim 4, wherein said first binding domain binds human Hsp70 at amino acid residues 454-461 or 450-463.

57. (previously presented) The bispecific molecule of claim 4, wherein said second binding domain binds human Bag-4 at amino acid residues 443-457.

58. (cancelled)